Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) Is Currently -156.25% Below Its 52-Week High, But Downside Potential Could Surprise You.
In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.69 million shares changing hands with its beta currently measuring 2.20. Company’s recent per share